BridgeBio Pharma, Inc. (BBIO)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 90M 180M 270M Q3 '21: 2.3M Q4 '21: 12.9M Q1 '22: 1.7M Q2 '22: 73.7M Q3 '22: 338K Q4 '22: 1.9M Q1 '23: 1.8M Q2 '23: 1.6M Q3 '23: 4.1M Q4 '23: 1.7M Q1 '24: 211.1M Q2 '24: 2.2M Q3 '24: 2.7M Q4 '24: 5.9M Q1 '25: 116.6M Q2 '25: 110.6M Q3 '25: 120.7M Q4 '25: 154.2M Q1 '26: 194.5M Q2 '26: 243.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

-80M 0 80M 160M 240M Q1 '22: 346K Q2 '22: 73M Q3 '22: -401K Q4 '22: 1.2M Q1 '23: 1.2M Q2 '23: 1M Q3 '23: 3.5M Q4 '23: 1.1M Q1 '24: 210.5M Q2 '24: 1.6M Q3 '24: 2.1M Q4 '24: 3.8M Q1 '25: 114M Q2 '25: 106.9M Q3 '25: 114.1M Q4 '25: 146.1M Q1 '26: 184.6M Q2 '26: 228.6M Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-240M -160M -80M 0 80M 160M 240M Q3 '21: -149.5M Q4 '21: -165.6M Q1 '22: -173.7M Q2 '22: -80.2M Q3 '22: -129.1M Q4 '22: -129.2M Q1 '23: -126.2M Q2 '23: -146.1M Q3 '23: -157.7M Q4 '23: -177.4M Q1 '24: 343K Q2 '24: -175.5M Q3 '24: -191.8M Q4 '24: -226M Q1 '25: -104.4M Q2 '25: -134.3M Q3 '25: -145.2M Q4 '25: -139.6M Q1 '26: -106M Q2 '26: -107.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-300M -200M -100M 0 100M 200M 300M Q3 '21: -161M Q4 '21: -152.3M Q1 '22: -201.3M Q2 '22: -2.6M Q3 '22: -140.2M Q4 '22: -140.6M Q1 '23: -142.7M Q2 '23: -160.7M Q3 '23: -179.5M Q4 '23: -170.3M Q1 '24: -36.2M Q2 '24: -75.5M Q3 '24: -164.3M Q4 '24: -267.4M Q1 '25: -169.6M Q2 '25: -183.8M Q3 '25: -184.9M Q4 '25: -194.6M Q1 '26: -166.6M Q2 '26: -155.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 6M 12M 18M Q3 '21: 1.5M Q4 '21: 1.2M Q1 '22: 1.3M Q2 '22: 700K Q3 '22: 739K Q4 '22: 647K Q1 '23: 651K Q2 '23: 599K Q3 '23: 598K Q4 '23: 598K Q1 '24: 598K Q2 '24: 598K Q3 '24: 598K Q4 '24: 2.1M Q1 '25: 2.6M Q2 '25: 3.7M Q3 '25: 6.6M Q4 '25: 8.1M Q1 '26: 9.9M Q2 '26: 15M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-240M -160M -80M 0 80M 160M 240M Q3 '21: -121.6M Q4 '21: -133.9M Q1 '22: -160.6M Q2 '22: -30.5M Q3 '22: -135.2M Q4 '22: -93.2M Q1 '23: -144.3M Q2 '23: -113.4M Q3 '23: -145.2M Q4 '23: -124.8M Q1 '24: -219.5M Q2 '24: 74.7M Q3 '24: -180.6M Q4 '24: -195.3M Q1 '25: -199.2M Q2 '25: -80.7M Q3 '25: -109.6M Q4 '25: -56.4M Q1 '26: -197.3M Q2 '26: -71.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-240M -160M -80M 0 80M 160M 240M Q3 '21: -128M Q4 '21: -136.4M Q1 '22: -161.5M Q2 '22: -32.9M Q3 '22: -135.9M Q4 '22: -94M Q1 '23: -144.3M Q2 '23: -113.8M Q3 '23: -145.7M Q4 '23: -125.3M Q1 '24: -220.2M Q2 '24: 74.6M Q3 '24: -180.7M Q4 '24: -195.4M Q1 '25: -199.2M Q2 '25: -81.3M Q3 '25: -110M Q4 '25: -56.5M Q1 '26: -197.3M Q2 '26: -71.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 70M 140M 210M Q2 '21: 146.8M Q3 '21: 146.7M Q1 '22: 145.9M Q2 '22: 146.7M Q3 '22: 147.9M Q1 '23: 152.6M Q2 '23: 160.5M Q3 '23: 163.3M Q1 '24: 178.7M Q2 '24: 187.6M Q3 '24: 188.5M Q1 '25: 190.1M Q2 '25: 190.5M Q3 '25: 191.9M Q1 '26: 194.8M Q2 '26: 195.8M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q3 '20: -3.41 Q4 '20: -3.80 Q1 '21: -4.20 Q2 '21: -3.83 Q3 '21: -3.91 Q4 '21: -3.92 Q1 '22: -4.09 Q2 '23: -3.75 Q3 '23: -3.90 Q4 '23: -3.94 Q1 '24: -3.22 Q2 '24: -2.63 Q3 '24: -2.41 Q4 '24: -2.87 Q1 '25: -3.55 Q2 '25: -4.11 Q3 '25: -4.20 Q4 '25: -3.77 Q1 '26: -3.73 Q2 '26: -3.56 Q4 '20 Q3 '21 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.